EnClear Therapies

EnClear Therapies

Private
Newburyport, MassachusettsHealthcare & Life Scienceshttps://www.encleartherapies.com/

Last Round

VC Round

Sep 4, 2024

Total Funding Raised

$13.3M

Company Overview

EnClear Therapies is a biotechnology company that develops device-based therapies designed to treat neurological diseases. The company's platform removes toxic proteins from cerebrospinal fluid (CSF) and provides controlled delivery of therapeutics to the central nervous system.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription, Government Contracts

AI Layer

Application

Keywords

CNS drug deliveryCSF managementblood-brain barrier deliverydrug delivery platformneurotechnologyneurotechtoxic protein removalcentral nervous systemCNScerebrospinal fluidCSFneurological deviceclosed-loop drug deliveryneuro-oncologypersonalized drug deliveryCSF dialysisALS treatmentleptomeningeal carcinomatosisAI-powered dosing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EnClear Therapies Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

EnClear Therapies Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
VC RoundSep 4, 2024
GrantJan 1, 2024
Series AFeb 19, 2020
SeedMar 14, 2019

Key People

Founding team and executive leadership

Anthony DePasqua

CEO & Board Director

Executive Team

EnClear Therapies Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 27, 2024

    Monthly visitors increased 207% MoM.

  • Sep 4, 2024

    Led by Sontag Innovation Fund and The Brain Tumor Investment Fund.

EnClear Therapies Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

EnClear Therapies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EnClear Therapies's valuation, stock price, and market status.

Firmographic Details

HeadquartersNewburyport, Massachusetts
Employee Range9
Year Founded2018
Last FundingSep 4, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.